GSK gravitates to India with £85m greenfield site for improved access

Three years after GSK chief executive Andrew Witty noted how the "center of gravity" of GSK was moving east towards India, China and this emerging part of the world and how India offered a huge manufacturing environment for it, the British multinational now seems set to walk the talk.

On 14 November, GSK announced plans to invest INR8.64bn (£85m) in a new Indian site, which will potentially make about eight billion tablets and one billion capsules annually for the Indian market and create 250 jobs